Preclinical work found that the ALK inhibitor alectinib enhances CAR‑T cell cytotoxicity against ALK‑mutant neuroblastoma, the study reports. Investigators demonstrated improved tumor cell killing when combining targeted ALK inhibition with CAR‑T therapy in laboratory models, suggesting a mechanistic rationale for combining small‑molecule ALK inhibitors with cell therapy in ALK‑driven pediatric cancers. The paper emphasizes translational opportunities, though clinical safety and dosing schedules for combining kinase inhibitors with CAR‑T cells will need careful evaluation.